Literature DB >> 12749423

Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy.

Efstratios M Kolibianakis1, Carola Albano, Jarl Kahn, Michel Camus, Herman Tournaye, Andre C Van Steirteghem, Paul Devroey.   

Abstract

OBJECTIVE: To compare ongoing implantation rates under two different GnRH antagonist protocols.
DESIGN: Randomized controlled trial.
SETTING: Tertiary referral center. PATIENT(S): One hundred eleven women undergoing ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). INTERVENTION(S): Ovarian stimulation with 150 IU recombinant-FSH (rec-FSH) starting on day 2 of the cycle and GnRH antagonist starting either on day 6 of stimulation (fixed group) or when a follicle of > or = 15 mm was present after at least 5 days of stimulation (flexible group). In the flexible group, the rec-FSH dose was increased to 250 IU when the antagonist was initiated. MAIN OUTCOME MEASURE(S): Ongoing implantation and pregnancy rate. RESULT(S): In patients with no follicle of > or = 15 mm present on day 6 of stimulation, a significantly lower ongoing implantation rate was observed if the flexible scheme was applied as compared with the fixed scheme of administration (8.8% vs. 23.9%, respectively). Exposure of the genital tract to LH or E2 from initiation of stimulation to antagonist administration was able to distinguish between pregnant and nonpregnant patients in the population studied. CONCLUSION(S): High exposure of the genital tract to LH and E2 in the early follicular phase is associated with a reduced chance of pregnancy in cycles stimulated with recombinant FSH and GnRH antagonist for IVF/ICSI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749423     DOI: 10.1016/s0015-0282(02)04920-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  36 in total

1.  Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study.

Authors:  Alberto Revelli; Alessandra Chiado'; Daniela Guidetti; Francesca Bongioanni; Valentina Rovei; Gianluca Gennarelli
Journal:  J Assist Reprod Genet       Date:  2012-05-29       Impact factor: 3.412

2.  Optimized hormonal stimulation is critical for production of viable embryos and establishment of subsequent implantation.

Authors:  Tao Tao; Alfred Robichaud; Sylvie Nadeau; Rejean Savoie; Bernard Gallant; Rodney J Ouellette
Journal:  J Assist Reprod Genet       Date:  2006-01-04       Impact factor: 3.412

3.  FSH time-concentration profiles before and after administration of 0.25 mg cetrorelix in the gnRH-antagonist multiple-dose protocol for ovarian hyperstimulation.

Authors:  G Griesinger; D Finas; A Alisch; K Roiha; A Schultze-Mosgau; A K Schröder; K Dafopoulos; K Diedrich; R Felberbaum
Journal:  J Assist Reprod Genet       Date:  2004-07       Impact factor: 3.412

4.  Cumulative exposure to high estradiol levels during the follicular phase of IVF cycles negatively affects implantation.

Authors:  Murat Arslan; Silvina Bocca; Ebru Ozturk Arslan; Hakan E Duran; Laurel Stadtmauer; Sergio Oehninger
Journal:  J Assist Reprod Genet       Date:  2007-02-16       Impact factor: 3.412

5.  Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.

Authors:  Kyono Koichi; Nakajo Yukiko; Kumagai Shima; Sasaki Sachiko
Journal:  J Assist Reprod Genet       Date:  2006-06-20       Impact factor: 3.412

6.  Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol.

Authors:  Chan Woo Park; Yu Im Hwang; Hwa Seon Koo; Inn Soo Kang; Kwang Moon Yang; In Ok Song
Journal:  Clin Exp Reprod Med       Date:  2014-12-31

7.  Addition of gonadotropin releasing hormone agonist for luteal phase support in in-vitro fertilization: an analysis of 2739 cycles.

Authors:  Erhan Şimşek; Esra Bulgan Kılıçdağ; Pınar Çağlar Aytaç; Gonca Çoban; Seda Yüksel Şimşek; Tayfun Çok; Bülent Haydardedeoğlu
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-06-01

8.  IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study.

Authors:  Hong Ye; Guo-ning Huang; Ping-hong Zeng; Li Pei
Journal:  J Assist Reprod Genet       Date:  2009-02-19       Impact factor: 3.412

9.  Is there a Need for Luteinizing Hormone (LH) Estimation in Patients Undergoing Ovarian Stimulation with Gonadotropin-Releasing Hormone (GnRH) Antagonists and Recombinant Follicle-Stimulating Hormone (rFSH)?

Authors:  Amar Ramachandran; Kshitij Jamdade; Pratap Kumar; Satish Kumar Adiga; Rajeshwari G Bhat; Sinatra R Ferrao
Journal:  J Clin Diagn Res       Date:  2014-01-12

10.  The value of delaying hCG administration to enable maturation of medium-sized follicles in patients undergoing superovulation for IVF/ICSI.

Authors:  Awoniyi O Awonuga; Karen Wheeler; Mili Thakur; Roohi Jeelani; Michael P Diamond; Elizabeth E Puscheck
Journal:  J Assist Reprod Genet       Date:  2017-09-30       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.